Jinain Pharmaceutics Reports Q3 Sales Below 300 Million KRW... KRX Adds Reasons for Listing Review

[Asia Economy Reporter Ji Yeon-jin] Jinain Pharmaceutical announced on the 14th that its sales revenue for the third quarter of this year was recorded at less than 300 million KRW.

In response, the Korea Exchange announced on the same day that an additional reason for the delisting suitability review was added, as the quarterly report submitted by Jinain Pharmaceutical confirmed that the sales revenue for the last quarter was less than 300 million KRW.